LEFRA 20

About

Lefra 20, containing Leflunomide 20mg, is an immunomodulatory agent used in the treatment of active rheumatoid arthritis (RA) and psoriatic arthritis. It acts as a disease-modifying anti-rheumatic drug (DMARD) by inhibiting dihydroorotate dehydrogenase, an enzyme involved in pyrimidine synthesis, thereby blocking the proliferation of activated T-lymphocytes. This mechanism helps to reduce inflammation, slow the progression of joint damage, and improve physical function in patients with these chronic autoimmune conditions. Leflunomide is often considered when methotrexate is not tolerated or is insufficient. Due to its long half-life and potential for significant side effects, careful patient selection, monitoring, and adherence to prescribed dosing are essential. Patients should be aware of the potential for liver toxicity and myelosuppression, requiring regular laboratory assessments during treatment.

Uses

• Treatment of active rheumatoid arthritis.
• Management of active psoriatic arthritis.
• Reduction of joint inflammation.
• Slowing the progression of joint damage.

Directions For Use

Take one tablet orally once daily, with or without food, as directed by your physician. Do not stop treatment abruptly without medical advice.

Benefits

• Reduces symptoms of rheumatoid arthritis.
• Slows joint damage progression.
• Improves physical function.
• Effective for psoriatic arthritis.
• Offers a once-daily dosing.
• Can be used when other DMARDs fail.

Side Effects

• Diarrhea
• Nausea
• Abdominal pain
• Hair loss (alopecia)
• Rash
• Headache
• Dizziness
• Liver enzyme elevations
• Hypertension
• Weight loss
• Weakness
• Leukopenia

Safety Measures

• Alcohol - Alcohol consumption should be avoided or minimized during leflunomide treatment due to an increased risk of hepatotoxicity.
• Pregnancy - Leflunomide is highly teratogenic and absolutely contraindicated in pregnancy. Women of childbearing potential must use reliable contraception.
• Breastfeeding - Leflunomide is excreted in breast milk and is contraindicated during breastfeeding due to potential serious adverse effects on the infant.
• Liver - Leflunomide is contraindicated in patients with pre-existing liver disease or significant hepatic impairment. Regular monitoring of liver function tests is mandatory.
• Kidney - Use with caution in patients with renal impairment. No specific dose adjustment guidelines exist, but close monitoring is advised.
• Lung - Rare cases of interstitial lung disease have been reported. Use with caution in patients with pre-existing lung conditions and monitor for new respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.